Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atheroscle...

Descripción completa

Detalles Bibliográficos
Autores principales: Triplitt, Curtis, Cersosimo, Eugenio, DeFronzo, Ralph A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941781/
https://www.ncbi.nlm.nih.gov/pubmed/20859539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941781/
https://www.ncbi.nlm.nih.gov/pubmed/20859539

Ejemplares similares